A once-weekly GLP-1 RA

A once-weekly GLP-1 RA

Getting your patients started with Ozempic® in a pre-filled FlexTouch® pen1

Convenient once-weekly dosing, with a 0.5 mg maintenance dose or 1 mg maximum maintenance dose1

START

STEP

OPTION TO ESCALATE

START

STEP

OPTION TO ESCALATE

START

for 4 week
(not a theraputic dose)

STEP

for 4 week
(MAINTENANCE dose)

OPTION TO ESCALATE

if additional glycemic control is needed after 4 weeks
(maximum maintenance dose)

Dose escalation: The starting dose of 0.25 mg is not a therapeutic dose. After 4 weeks, the dose should be increased to 0.5 mg once weekly. If additional glycemic control is needed after 4 weeks, the dose may be increased to 1 mg once weekly to further improve glycemic control (1 mg once weekly is the maximum recommended dose).

Dose escalation: The starting dose of 0.25 mg is not a therapeutic dose. After 4 weeks, the dose should be increased to 0.5 mg once weekly. If additional glycemic control is needed after 4 weeks, the dose may be increased to 1 mg once weekly to further improve glycemic control (1 mg once weekly is the maximum recommended dose).

Missed dose:

Administer a missed dose as soon as possible within 5 days after the missed dose. If more than 5 days have passed, the missed dose should be skipped, and the next dose administered on the regularly scheduled day.


No dose adjustments required in the following special populations1

Patients
≥ 65 years

Patients with
renal insufficiency

Please refer to the Ozempic® Product Monograph for complete dosing and administration instructions.

Contact Us

Novo Nordisk would like every healthcare practitioner to be able to obtain information as easily and quickly as possible.
If you need information about Ozempic®, please contact:

Novo Nordisk Canada Inc.
101-2476 Argentia Road
Mississauga, Ontario
L5N 6M1

Business hours are:
Monday to Friday from
8:30 a.m. to 5:00 p.m. EST

Main number:
905-629-4222
Toll-free:
1-800-465-4334

Main fax number:
905-629-8662
Toll-free fax number:
1-844-465-2225